Fragile X Syndrome Market Research Report 2022: Size and Trends, Epidemiology and Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecasts, 2021-2030 – ResearchAndMarkets.com

Fragile X Syndrome Market Research Report 2022: Size and Trends, Epidemiology and Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecasts, 2021-2030 – ResearchAndMarkets.com




Fragile X Syndrome Market Research Report 2022: Size and Trends, Epidemiology and Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecasts, 2021-2030 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Fragile X Syndrome Market Size and Trend Report including Epidemiology and Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast, 2021 – 2030” drug pipelines has been added to ResearchAndMarkets.com’s offering.

The two clinically and commercially relevant segments considered for the classification of FXS in this report are segmented into three groups by age: pediatric patients aged 0-11 years, adolescent patients aged 12-17, and adult patients aged 18+.

This report covers 2MM (US and Germany) and provides an Excel-based forecast model for the Fragile X Syndrome market through 2030.

Key Highlights

  • Forecasts include two countries
  • Forecasts cover three time points: base year, 5-year, and 10-year
  • There are currently no approved therapies available for FXS, so prescribed treatments are exclusively off-label products that target individual symptoms of the disease. The most frequently used drug classes are: selective serotonin reuptake inhibitors (SSRIs), psychostimulants, antipsychotic agents, anticonvulsant agents, and antihypertensive anxiolytics.
  • The current treatment options that target FXS symptoms of irritability and aggression are often sedating and diminish patients’ interaction with their environment. This prevents disruptive behavior but negatively affects the patients’ quality of life. There is a need for interventions that suppress aggressive behavior without side effects.
  • Products in Phase I and II stages of development account for 89.7% of the FXS pipeline, while limited development is seen in Phase III trials with only one drug currently in development.
  • The FXS market will exhibit significant growth between 2020 and 2030, driven by the entry of four pipeline agents. Notably, the sales of high-priced pipeline agents, Zygel, zatolmilast, and trofinetide represent the most impactful drivers of growth.

Scope

  • Overview of FXS, including epidemiology, symptoms, diagnosis, and disease management.
  • Annualized FXS therapeutics market revenue, cost of therapy per patient, and treatment usage patterns in three patient segments (pediatric patients aged 0-11 years, adolescent patients aged 12-17, and adult patients aged 18+) forecast from 2020 to 2030.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications of these factors for the FXS therapeutics market.
  • Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for FXS treatment. The most promising candidates in Phase III and Phase IIb development are profiled.
  • Analysis of the current and future market competition in the global FXS therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Key Topics Covered:

1 Executive Summary

1.1 Executive Summary

2 Disease Overview

2.1 Overview of Fragile X Syndrome

2.2 Fragile X Syndrome SWOT Analysis

2.3 Classification of Fragile X Syndrome

3 Epidemiology

3.1 Diagnosed Prevalent Cases of Fxs, Men and Women, 2020-30

3.2 Sources and Methodology

4 Current Treatment Options

4.1 Treatment Paradigm

4.2 Current Treatment Options

4.3 Product Profile: Ssris (Fluoxetine, Sertraline, Citalopram, Escitalopram)

4.4 Product Profile: Other Antidepressants (Venlafaxine, Bupropion, Trazadone)

4.5 Product Profile: Psychostimulants (Methylphenidate Hydrochloride)

4.6 Product Profile: Atypical Antipsychotics (Aripiprazole, Risperidone)

4.7 Product Profile: Anticonvulsants (Lamotrigine, Carbamazepine, Sodium Valproate)

4.8 Product Profile: Antihypertensive Anxiolytics (Clonidine, Guanfacine)

4.9 Product Profile: Benzodiazepines (Clonazepam, Diazepam)

4.10 Product Profile: Lithium (Lithium Carbonate)

5 Unmet Needs and Opportunities

5.1 Unmet Needs in Fragile X Syndrome

6 R&D Strategies

6.1 Trends in Deal-Making in Fxs

6.2 Trends in Deal-Making in Fxs

7 Pipeline Assessment

7.1 Fragile X Syndrome Pipeline Overview

7.2 Late-Stage Pipeline Agents

7.3 Product Profile: Zynerba Pharmaceuticals’ Zygel

7.4 Product Profile: Tetra Therapeutics’ Zatolmilast

7.5 Product Profile: Confluence Pharmaceuticals’ Acamprosate Calcium Sr

7.6 Product Profile: Neuren Pharmaceuticals’ and Acadia Pharmaceuticals’ Trofinetide

8 Market Outlook

8.1 Fragile X Syndrome Market Forecast

8.2 Market Drivers and Barriers

9 Appendix

Companies Mentioned

  • Acadia Pharmaceuticals
  • Advanz Pharma Corp
  • Boehringer Ingelheim
  • Confluence Pharmaceuticals
  • Eli Lilly
  • GlaxoSmithKline
  • H. Lundbeck
  • Janssen
  • Neuren Pharmaceuticals
  • Novartis
  • Otsuka Pharmaceuticals
  • Sanofi
  • Takeda
  • Viatris
  • Tetra Therapeutics
  • Zynerba Pharmaceuticals

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/tw0iow

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900